Colorectal cancer remains one of the most frequently diagnosed and deadliest malignancies worldwide, ranking near the top of global tables for both incidence and mortality. When the disease is discovered early, surgery can be curative, but once tumor cells have spread to regional lymph nodes or distant organs, systemic chemotherapy becomes the backbone of treatment. The FOLFOX regimen—oxaliplatin combined with 5-fluorouracil and leucovorin—has anchored first-line therapy for advanced colorectal cancer for years, shrinking tumors, delaying recurrence, and prolonging survival. Its Achilles heel is acquired chemoresistance: many tumors respond at first, then evolve the ability to survive both drugs, leaving oncologists with a shrinking arsenal. Deciphering the machinery that confers this resilience has become one of the most urgent quests in gastrointestinal oncology, because a resistance mechanism, once identified, can itself be converted into a therapeutic target.

The enzyme now implicated in that process belongs to a family of related enzymes known as polypeptide N-acetylgalactosaminyltransferases, or GALNTs, of which the human genome encodes roughly twenty functional members. These enzymes reside in the Golgi apparatus, the cell’s protein-processing warehouse, where they initiate O-GalNAc glycosylation: the attachment of the sugar N-acetylgalactosamine onto serine or threonine amino acids within newly made proteins. Far from being a cosmetic modification, this mucin-type glycosylation alters how proteins fold, how they travel to the cell surface, how long they persist there, and how powerfully they transmit signals. Over the past decade, cancer researchers have learned that individual GALNT members can behave as oncogenic drivers, and GALNT5 in particular has a growing rap sheet. An earlier study linked it to resistance against FOLFIRINOX—the pancreatic cancer analog of FOLFOX—in pancreatic ductal adenocarcinoma, operating through a MYH9/NOTCH/DNA damage response axis. Whether the same enzyme played a comparable double role in colorectal cancer, driving both malignant progression and resistance to oxaliplatin and 5-fluorouracil, had not been resolved.

To close that gap, the team combined computational and experimental approaches. Integrated bioinformatics analyses first flagged GALNT5 expression across colorectal cancer cell lines, and the finding was confirmed with RNA sequencing, quantitative reverse-transcription PCR, and Western blotting, using the normal colonic epithelial cell line NCM460 as a baseline. The researchers then engineered two chemoresistant daughter lines from the colorectal cancer cell line LoVo: one chronically exposed to oxaliplatin until it became resistant, designated LoVo/L, and another trained on 5-fluorouracil, designated LoVo/5FU. RNA sequencing of these models mapped the signaling pathways and effector genes that bend when GALNT5 activity changes. Cell proliferation was quantified with CCK-8 assays, invasion was measured in Transwell chambers, and apoptosis was monitored as GALNT5 levels were manipulated. Because GALNT enzymes work by chemically modifying proteins rather than altering genes directly, the team also deployed lectin-based assays capable of detecting the sugar additions themselves—a methodological decision that would prove pivotal for the mechanistic experiments. Finally, the pharmacology was tested with 740Y-P, a synthetic agonist that switches on phosphoinositide 3-kinase, allowing the team to interrogate whether the PI3K pathway sat downstream of the enzyme.

The expression screen produced a clear verdict: GALNT5 is significantly upregulated in colorectal cancer cell lines compared with normal colonic epithelium. More importantly, that overexpression was not a passive byproduct of malignancy. When the researchers silenced GALNT5, the cancer cells’ behavior shifted on every metric tested. Proliferation slowed markedly, the capacity to invade through Transwell membranes dropped, and apoptosis increased in both the parental cells and the drug-resistant derivatives. In effect, GALNT5 was acting as a tumor-promoting gene, sustaining the proliferative drive, motility, and survival advantages that define aggressive disease. Crucially, the enzyme’s grip extended to the resistant sublines as well: removing GALNT5 weakened even cells that had already learned to endure chemotherapy. Because the parental and resistant lines are otherwise genetically matched, the parallel effects argue that GALNT5 is functionally upstream of both the aggressive growth phenotype and the resistance phenotype, not merely a passenger carried along during tumor evolution.

The pivotal experiments concerned the resistant cells themselves. When GALNT5 was knocked down in LoVo/L and LoVo/5FU cells, their sensitivity to oxaliplatin and 5-fluorouracil rebounded—the drugs regained their capacity to kill cells they had previously failed to eliminate. That observation alone would have been notable, but the team went further with a decisive control. They treated the GALNT5-silenced, drug-vulnerable cells with 740Y-P, a small-molecule agonist that directly activates phosphoinositide 3-kinase (PI3K), the enzyme that ignites the Akt survival pathway. The protective effect of losing GALNT5 evaporated: with PI3K forcibly reactivated, the cells clawed back much of their resistance to both drugs. The rescue experiment established that GALNT5 works through the PI3K/Akt axis rather than through some parallel route, and it placed a well-mapped, heavily drugged signaling cascade at the heart of the resistance mechanism.

The remaining question was how an enzyme inside the Golgi reaches a signaling pathway in the cytoplasm. The answer emerged from lectin pull-down assays using VVL, or Vicia villosa lectin, a plant-derived protein with a strong affinity for terminal N-acetylgalactosamine residues. By using VVL to fish out sugar-decorated proteins, the researchers confirmed that GALNT5 directly mediates O-GalNAc glycosylation of the epidermal growth factor receptor, or EGFR—the membrane receptor that serves as a master upstream activator of PI3K/Akt signaling. Glycosylation is known to shape how growth-factor receptors mature, localize, and signal, and the new data show that GALNT5’s sugar additions potentiate EGFR’s pro-growth output. Downstream, the team documented a second, equally consequential effector: depletion of GALNT5 caused downregulation of ABCC1, an ATP-binding cassette transporter also called multidrug resistance-associated protein 1, whose function is to pump foreign molecules—including many chemotherapeutics—out of the cell. ABCC1 overexpression is a classic textbook mechanism of multidrug resistance, and the finding that a glycosyltransferase controls it in vitro and in vivo ties the sugar code directly to the drug-export machinery. The in vivo arm of the study, conducted under approval from an institutional animal care committee in accordance with the Declaration of Helsinki, confirmed that GALNT5 depletion suppressed ABCC1 in living tumor models as well as in culture dishes.

The study lands in a research landscape that is rapidly converging on the same theme from multiple angles. The earlier pancreatic cancer work established GALNT5 as an oncogenic driver of FOLFIRINOX resistance through a different downstream axis, implicating the cytoskeletal protein MYH9, the NOTCH developmental pathway, and the DNA damage response. Other family members tell similar stories: GALNT2, targeted by the microRNA miR-139-5p, has been shown to promote proliferation in clear cell renal cell carcinoma by interfering with LATS2 activation. A separate multi-omics analysis has even cast post-translational modification networks—including glycosylation—as central regulators of colorectal cancer progression and immune evasion. What emerges across these reports is that GALNT enzymes are not passive housekeepers of protein decoration; in cancer, individual members can recalibrate receptor signaling, cell-cycle machinery, and drug-response pathways simultaneously. The colorectal study adds a mechanistic template that is especially clean: sugar modification of a receptor tyrosine kinase at the top, transporter deregulation at the bottom, and a single survival pathway connecting the two.

For clinicians and drug developers, the appeal of GALNT5 is its potential double utility. As a biomarker, measuring GALNT5 expression in tumor tissue could, in principle, flag patients whose cancers are biologically primed to resist oxaliplatin and 5-fluorouracil before the first infusion, allowing oncologists to select alternative regimens or plan intensification from the outset. As a target, the enzyme offers an intervention point upstream of two heavily validated pathways—PI3K/Akt signaling and the ABCC1 drug pump—meaning that a GALNT5 inhibitor could, in theory, suppress growth and dismantle chemoresistance at the same time. Combination strategies that pair such an inhibitor with existing FOLFOX chemotherapy are the most obvious translational path. Important caveats remain, however. The study, published as an open-access early-release article that is citable ahead of the final version of record, rests on cell lines, xenograft evidence, and molecular assays rather than patient trials. GALNT enzymes also serve essential glycosylation functions in healthy tissues, particularly in mucin-producing epithelia, so any therapeutic inhibition would need to demonstrate an acceptable safety window.

What the study ultimately delivers is a complete, testable chain of causation. An overexpressed Golgi enzyme glycosylates EGFR; hyperactive EGFR ignites PI3K/Akt signaling; and that pathway simultaneously fuels proliferation and invasion while sustaining the ABCC1 pump that expels oxaliplatin and 5-fluorouracil from the cell. Every node in the chain is now a candidate point of intervention, and the weakest link—GALNT5 itself—has the distinction of sitting at the very top. The research was funded by the Jilin Provincial Special Project for Health Research Talents and was led by co-first authors Qiong Wu and Liehao Yang, with Changmiao Wang as corresponding author, drawing on investigators from the First Affiliated Hospital of Dalian Medical University and the China-Japan Union Hospital of Jilin University. If subsequent studies confirm that inhibiting GALNT5 can resensitize human tumors as reliably as it does laboratory models, one of colorectal cancer’s most resilient survival tricks—written, improbably, in sugar—may finally become one of its most exploitable weaknesses.